AR129299A1 - Compuestos para modular complejos de factores asociados a brg1 o brm (baf) - Google Patents

Compuestos para modular complejos de factores asociados a brg1 o brm (baf)

Info

Publication number
AR129299A1
AR129299A1 ARP230101168A ARP230101168A AR129299A1 AR 129299 A1 AR129299 A1 AR 129299A1 AR P230101168 A ARP230101168 A AR P230101168A AR P230101168 A ARP230101168 A AR P230101168A AR 129299 A1 AR129299 A1 AR 129299A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
cancer
alkyl
halo
hydrogen
Prior art date
Application number
ARP230101168A
Other languages
English (en)
Spanish (es)
Inventor
Shawn E R Schiller
Solymar Negretti
David S Huang
Kevin J Wilson
Melek Nihan Ucisik
Richard Caldwell
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of AR129299A1 publication Critical patent/AR129299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP230101168A 2022-05-11 2023-05-11 Compuestos para modular complejos de factores asociados a brg1 o brm (baf) AR129299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263340927P 2022-05-11 2022-05-11

Publications (1)

Publication Number Publication Date
AR129299A1 true AR129299A1 (es) 2024-08-07

Family

ID=86732694

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101168A AR129299A1 (es) 2022-05-11 2023-05-11 Compuestos para modular complejos de factores asociados a brg1 o brm (baf)

Country Status (17)

Country Link
US (2) US12139487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4522280A1 (cg-RX-API-DMAC7.html)
JP (2) JP7531656B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250024923A (cg-RX-API-DMAC7.html)
CN (1) CN119677738A (cg-RX-API-DMAC7.html)
AR (1) AR129299A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023270055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252955A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003450A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015229A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000231A (cg-RX-API-DMAC7.html)
IL (1) IL316531A (cg-RX-API-DMAC7.html)
JO (1) JOP20240250A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013838A (cg-RX-API-DMAC7.html)
PE (1) PE20250261A1 (cg-RX-API-DMAC7.html)
TW (2) TW202506693A (cg-RX-API-DMAC7.html)
WO (1) WO2023220219A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
WO2025008060A1 (en) * 2023-07-05 2025-01-09 Janssen Pharmaceutica Nv 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
WO2025099307A1 (en) * 2023-11-10 2025-05-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
US20250304542A1 (en) * 2024-03-11 2025-10-02 Enanta Pharmaceuticals, Inc. Fused Heterobicyclic Antiviral Agents
WO2025209520A1 (zh) * 2024-04-03 2025-10-09 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2025237242A1 (zh) * 2024-05-14 2025-11-20 上海和誉生物医药科技有限公司 一种smarca2抑制剂及其应用
CN118930537B (zh) * 2024-07-23 2025-05-13 上海信诺维生物医药有限公司 一种抑制brm的化合物
CN118930561B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种稠环化合物
CN118908980B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种多环化合物
WO2026046365A1 (zh) * 2024-08-30 2026-03-05 上海齐鲁制药研究中心有限公司 Smarca2抑制剂及其制备方法和用途
WO2026057002A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 一种烯炔类化合物及其应用
WO2026061424A1 (zh) * 2024-09-18 2026-03-26 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2026131996A1 (en) * 2024-12-17 2026-06-25 Onco3R Therapeutics Bv Fused azines for the treatment of cancer
WO2026158636A1 (zh) * 2025-01-26 2026-07-30 江苏恒瑞医药股份有限公司 一种三环骨架芳酰胺类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
BR112022015110A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
BR112022015109A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CA3198317A1 (en) 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof

Also Published As

Publication number Publication date
TW202411228A (zh) 2024-03-16
JOP20240250A1 (ar) 2024-11-07
JP7531656B2 (ja) 2024-08-09
AU2023270055A1 (en) 2024-11-28
MX2024013838A (es) 2025-03-07
KR20250024923A (ko) 2025-02-20
CO2024015229A2 (es) 2025-03-06
TWI864749B (zh) 2024-12-01
CA3252955A1 (en) 2023-11-16
DOP2024000231A (es) 2024-12-15
PE20250261A1 (es) 2025-01-29
EP4522280A1 (en) 2025-03-19
JP2023168298A (ja) 2023-11-24
TW202506693A (zh) 2025-02-16
US20230365560A1 (en) 2023-11-16
IL316531A (en) 2024-12-01
CN119677738A (zh) 2025-03-21
US12139487B2 (en) 2024-11-12
WO2023220219A1 (en) 2023-11-16
US20250066354A1 (en) 2025-02-27
JP2024156779A (ja) 2024-11-06
CL2024003450A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
PE20240687A1 (es) Compuestos de indazol como inhibidores de cinasas
AR126108A1 (es) Tratamientos para la degradación del braf mutante
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR093364A1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR091654A1 (es) COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
AR119910A1 (es) DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL
AR111279A1 (es) Derivados heterocíclicos útiles como inhibidores duales de atx / ca
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR091490A1 (es) Antagonistas de iap
AR116464A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR112907A1 (es) Pirazoles inhibidores de monoacilglicerol lipasa (magl)
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR118081A1 (es) Inhibidores de enzimas
AR116400A1 (es) Compuesto de imidazopiridinona
AR108387A1 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
PE20212327A1 (es) Ciertos compuestos de pladienolida y metodos de uso
AR034390A1 (es) Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
AR113887A1 (es) Derivados de indol macrocíclicos sustituidos con cloro
AR123701A1 (es) Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
AR097754A1 (es) Derivados sustituidos de fenilalanina